Achmea Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Achmea Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,084	Closed	-$411K	–	507
2023 Q2	$411K	Hold	1,084	–	–	0.01%	506
2023 Q1	$519K	Hold	1,084	–	–	0.02%	458
2022 Q4	$427K	Buy	1,084 +1,040	+2,364%	+$420K	0.01%	503
2022 Q3	$19K	Sell	44 -2,540	-98%	-$1.27M	﹤0.01%	609
2022 Q2	$1.28M	Hold	2,584	–	–	0.04%	366
2022 Q1	$1.46M	Sell	2,584 -1,445	-36%	-$871K	0.04%	387
2021 Q4	$3.04M	Buy	+4,029	New	+$3.02M	0.14%	142
2020 Q1	–	Sell	-2,540	Closed	-$940K	–	291
2019 Q4	$940K	Buy	+2,540	New	+$895K	0.04%	377

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Achmea Investment Management's BIO Position: Q3 2023 in Review

Achmea Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 1,084 shares — an estimated $411K sold.

Achmea Investment Management first reported a position in BIO in Q4 2019 and held it in 8 quarters. The position peaked at $3.04M in Q4 2021. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

Achmea Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
Achmea Investment Management sold 1,084 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $411K.
Achmea Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 8 quarters.
Achmea Investment Management's Bio-Rad Laboratories Class A position peaked at $3.04M in Q4 2021.
467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Achmea Investment Management's 13F filing for Q3 2023, filed 6 Nov 2023.